GlassScriptPhysician profile
Jeffrey Charles Meyer
NPI 1962559377
$5,332.39
in general payments reported to CMS, 2019-2025
36 companies · $844 in 2025
The $844 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $257 · 2021: $448 · 2022: $453 · 2023: $1,270 · 2024: $1,242 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $639.39 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $626.77 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $399.23 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Abbvie INC. | $395.78 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $351.82 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.09 | 2021-2025 | Caplyta |
| Indivior INC. | $236.37 | 2019-2024 | Sublocade |
| Axsome Therapeutics, INC. | $227.53 | 2023-2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $200.97 | 2019-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $196.41 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $156.90 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $145.00 | 2019-2025 | Ingrezza |
| Allergan, INC. | $142.85 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $129.05 | 2022-2025 | Qelbree, Qelbree |
| Noven Therapeutics, LLC | $120.84 | 2023-2025 | Xelstrym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $113.40 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $105.50 | 2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $99.54 | 2019-2023 | Belsomra |
| Harmony Biosciences LLC | $78.00 | 2023-2024 | Wakix |
| Ironshore Pharmaceuticals INC. | $77.93 | 2024 | |
| Braeburn INC. | $75.03 | 2024 | Brixadi |
| Jazz Pharmaceuticals INC. | $72.83 | 2019-2022 | |
| Shire North American Group INC | $67.51 | 2019 | |
| Bausch Health US, LLC | $56.67 | 2022-2023 | Aplenzin, Wellbutrin |
| Orexo US, INC. | $49.43 | 2019 | |
| Adlon Therapeutics L.P. | $46.15 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $41.35 | 2019 | |
| Alfasigma USA, INC. | $37.81 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.00 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $30.48 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $26.65 | 2019 | |
| Vertical Pharmaceuticals, LLC | $24.98 | 2019 | |
| Biogen, INC. | $24.62 | 2024 | |
| Almatica Pharma LLC | $20.84 | 2023 | Loreev Xr, Sertraline Hcl |
| Tris Pharma INC | $20.37 | 2022 | |
| Neos Therapeutics, LP | $16.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.